Government Reform Cmte. Ephedra Hearing Still Possible Pending FDA Stance
This article was originally published in The Tan Sheet
Executive Summary
The House Government Reform Committee still is considering holding a hearing on FDA's position regarding ephedrine alkaloid-containing dietary supplements.
You may also be interested in...
Government Reform Committee
House hearing on dietary supplement issues scheduled to be held Feb. 28. Potential points of discussion and testimony include Codex, ephedra, Pearson implementation and GMPs. Committee Chairman Dan Burton (R-Ind.) postponed a Dec. 27 hearing on FDA's position regarding ephedrine alkaloid-containing supplements after receiving confirmation from FDA it had no plans to act immediately on the matter (1"The Tan Sheet" Jan. 8, p. 11)
Government Reform Committee
House hearing on dietary supplement issues scheduled to be held Feb. 28. Potential points of discussion and testimony include Codex, ephedra, Pearson implementation and GMPs. Committee Chairman Dan Burton (R-Ind.) postponed a Dec. 27 hearing on FDA's position regarding ephedrine alkaloid-containing supplements after receiving confirmation from FDA it had no plans to act immediately on the matter (1"The Tan Sheet" Jan. 8, p. 11)
Government Reform Committee
House hearing on dietary supplement issues scheduled to be held Feb. 28. Potential points of discussion and testimony include Codex, ephedra, Pearson implementation and GMPs. Committee Chairman Dan Burton (R-Ind.) postponed a Dec. 27 hearing on FDA's position regarding ephedrine alkaloid-containing supplements after receiving confirmation from FDA it had no plans to act immediately on the matter (1"The Tan Sheet" Jan. 8, p. 11)